BioSpace News Archive

InnovaQor, Inc. (A Nevada corporation) (OTC: VMCS), today announced that it will become a fully SEC reporting company when its Form 10-12G becomes automatically effective on September 27, 2022.

ObvioHealth, a pioneering virtual research organization (VRO), announces the launch of ObvioGo, a next-generation decentralized clinical trial platform and mobile application powered to deliver stronger evidence of therapeutic efficacy and safety.

OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its PremiOM™ Ulcerative Colitis (UC) and Crohn’s Disease (CD) datasets, providing comprehensive, clinically-deep and representative data to support a broad assortment of research needs.

Sunstone Therapies, a company dedicated to treating the psychological effects of cancer, announces today the launch of a new clinical trial to test the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant post-traumatic stress disorder (PTSD).

Neurovation Labs, Inc., a biotechnology company targeting physiological biomarkers of Post-traumatic Stress Disorder (PTSD) for comprehensive diagnosis and treatment, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,439,715, on September 13, 2022.

Illumina, Inc. announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is a world-class company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.

Amylyx Pharmaceuticals, Inc. today announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial that evaluated the safety, efficacy, and survival benefits of AMX0035 in adult participants with amyotrophic lateral sclerosis (ALS) are now available in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be sponsoring, presenting and hosting a booth at the Caribbean Public Health Agency (CARPHA) 66th Annual Health Research Conference.

Prolific Machines, a next generation biotechnology company, is emerging from stealth today by announcing their massively oversubscribed Seed and Series A financings, led by the best VCs in the space.

Patients at St. Elizabeth Healthcare now have the ability to screen for 50 different types of cancer, thanks to a new blood test launched in June 2022.